What Narodowy Instytut Onkologii im. Marii Skłodowskiej does

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy – Oddział w Gliwicach (National Oncology Institute, Maria Skłodowska-Curie Memorial, State Research Institute – Gliwice Branch) is a Polish state-owned specialized oncology hospital and research center, operating as the Gliwice branch of the National Oncology Institute headquartered in Warsaw with a third branch in Kraków. The institute provides comprehensive cancer care across the full clinical pathway: diagnostic imaging including PET, scintigraphy, and radiology; surgical oncology; radiotherapy and brachytherapy; systemic therapies (chemotherapy, immunotherapy, hormone therapy); bone marrow transplantation; nuclear medicine; and supportive services including rehabilitation, nutritional counseling, genetic counseling, and palliative care. It employs 340+ physicians and 420+ nurses, serves 1,200+ patients daily, and records 54,000+ annual hospitalizations, serving as a regional referral center for the Silesia region within Poland's public health system.

Technology and research infrastructure centers on a multi-building campus with a dedicated Radiotherapy Building, PET building with radiopharmacy and medical physics, and an isotope therapy facility. Research assets include the Centrum Badań Translacyjnych i Biologii Molekularnej Nowotworów (Translational Cancer Research and Molecular Biology Center), a Biobank for biological sample storage, a Centrum Medycyny Cyfrowej (Digital Medicine Center), and a Clinical Trials Support Center. The Oddział Terapii Izotopowej (Isotope Therapy Department), launched on June 22, 2025, is positioned as a comprehensive theranostic center of strategic national importance. Patient-facing digital tools include e-Rejestracja for online appointment booking, the eCareMed Silesian Patient Platform, and integration with Poland's national IKP (Internetowe Konto Pacjenta) patient account system.

The business model is public-sector: the institute is fully state-owned with no private shareholders, and revenue is primarily generated through service contracts with Narodowy Fundusz Zdrowia (NFZ), Poland's national health insurer, on a subscription/fee-for-service basis. Supplementary revenue streams include commercial fee-for-service pricing for uninsured patients and competitive research grants from sources including Agencja Badań Medycznych (TRANSMED I grant of 11,123,761 PLN), European Union programs, and Norway Grants. Patient access is through referrals within Poland's public health system, with the institute participating as a regional node in the Krajowa Sieć Onkologiczna (National Oncology Network).

Name

Narodowy Instytut Onkologii im. Marii Skłodowskiej

Legal name

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy – Oddział w Gliwicach

Website

https://en.io.gliwice.pl

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Narodowy Instytut Onkologii – Gliwice Branch is a Polish state-owned specialized oncology hospital and research institute providing comprehensive cancer diagnosis, treatment, and translational research to oncology patients across the Silesia region and Poland.

Ownership category

akta.pro rank

Product category

Oncology Healthcare Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Surgical Oncology (HLAKAFAG), Radiation Oncology (HLAKAFAC), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Oncology diagnostics
• Cancer treatment
• Radiotherapy services
• Nuclear medicine
• Clinical research

Headquarters

HQ city

Gliwice

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Public Healthcare Services (Narodowy Fundusz Zdrowia): The institute operates as a public healthcare provider under Poland's national health insurance system. Medical services are primarily funded through contracts with Narodowy Fundusz Zdrowia (NFZ), Poland's public health insurer. Citizens with public health insurance receive covered services.
2. Commercial/Private Patient Services: Fee-for-service medical care for patients without public health insurance coverage or seeking services outside the public system. The institute publishes a commercial pricing list (Cennik dla pacjentów komercyjnych).
3. Research Grants and External Funding: The institute receives research funding from government sources including the Agency for Medical Research (Agencja Badań Medycznych), European Union funds, and national budget allocations. Example: 11,123,761 PLN TRANSMED I grant for targeted radioisotope therapy research.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

The institute provides comprehensive oncology healthcare services, delivering end-to-end cancer diagnosis and treatment (surgical oncology, radiotherapy, brachytherapy, nuclear medicine, PET diagnostics, systemic therapies, and bone marrow transplantation). It is also a state research institute conducting translational cancer research and operating research infrastructure (Translational Cancer Research Center, Biobank, Digital Medicine Center, Clinical Trials Support Center). Patient-facing digital tools include e-Rejestracja, Portal Pacjenta, and the eCareMed platform for the Silesia region.

Product overview

Narodowy Instytut Onkologii is a comprehensive oncology center providing integrated cancer care services. The institution operates as a specialized oncology hospital offering diagnostic imaging (PET, scintigraphy, radiology), surgical oncology, radiotherapy, brachytherapy, systemic treatments (chemotherapy, hormone therapy, immunotherapy), and nuclear medicine services. The institute provides patient-facing digital services including e-Rejestracja for online appointment booking, Portal Pacjenta for medical records access, and eCareMed platform for the Silesian region. Scientific infrastructure includes the Translational Research Center, Biobank, Digital Medicine Center, and Clinical Trials Support Center supporting advanced cancer research and new treatment development.

Differentiator

Problem solved

Functional benefit

Products and services

• Comprehensive Cancer Diagnosis Comprehensive cancer diagnostic services including laboratory medicine, radiology, nuclear medicine, tumor pathology, and PET (Positron Emission Tomography) imaging for oncology patients across all cancer types.
• Surgical Oncology Surgical oncology services across cancer types, delivered via dedicated operating theaters with anesthesiology and intensive care support.
• Radiotherapy Radiotherapy treatment services for cancer patients delivered from a dedicated Radiotherapy Building. Does not require a referral for access.
• Brachytherapy Internal radiation therapy (brachytherapy) services for cancer patients. Does not require a referral for access.
• Isotope Therapy (Oddział Terapii Izotopowej) Comprehensive theranostic center for cancer diagnosis and treatment using radioisotope therapies, operating as part of the Department of Nuclear Medicine and Oncological Endocrinology. The center is described as strategically important for the development of modern oncology in Poland.
• Systemic Therapy (Chemotherapy, Immunotherapy, Hormone Therapy) Systemic cancer treatments including chemotherapy, immunotherapy, and hormone therapy administered via the Chemotherapy Day Ward and dedicated systemic therapy clinics.
• Bone Marrow Transplantation and Oncohematology Bone marrow transplantation services and oncohematology care for patients with hematologic cancers, delivered through the dedicated bone marrow transplant and oncohematology clinic.
• Clinical Trials Support (Centrum Wsparcia Badań Klinicznych) Clinical Trials Support Center providing infrastructure and coordination for clinical research, enabling patient access to clinical trials and experimental oncology therapies.
• Genetic Counseling and Family Risk Assessment Genetic counseling and family risk assessment services for cancer predisposition, delivered through the institute's genetic clinic.
• Rehabilitation and Nutritional Support Rehabilitation services and nutritional counseling for oncology patients, delivered through the rehabilitation and nutritional clinic in the Old Building.
• e-Rejestracja (Electronic Registration) Online electronic registration platform enabling patients to book oncology appointments via mpi.io.gliwice.pl.
• eCareMed Silesian Patient Platform Silesian Patient Platform (Śląska Platforma Pacjenta) accessible via app.ecaremed.pl, enabling patients to access and manage their healthcare information and appointments.

Quantifiable outcome

• 1200+ daily patient visits
• +1 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Górnośląska Fundacja Onkologiczna (Upper Silesian Oncology Foundation)coreStrategic or Co-development PartnerLocal oncology foundation supporting cancer patients and research. The institute collaborates with the foundation for patient support services and awareness programs.
• Narodowy Fundusz Zdrowia (NFZ)coreChannel Partner/ Reseller/ DistributorPoland's national health insurer. The institute operates under public healthcare contracts with NFZ for providing oncology services to insured citizens.
• Krajowa Sieć Onkologiczna (National Oncology Network)coreStrategic or Co-development PartnerCoordinated oncology care network ensuring standardized cancer care pathways. The institute serves as a key participant in the network's regional structure.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Others

• German Cancer Research Center (DKFZ): Germany's national cancer research institute; comparable as a publicly funded translational cancer research partner rather than a direct clinical-care competitor, often co-funding European oncology consortia with Gliwice's parent institute.

Broad incumbents

• Charité Comprehensive Cancer Center: University-hospital oncology program within Charité in Berlin, providing multi-disciplinary oncology care and translational research; comparable in combining public-mission care with European research funding.
• Gustave Roussy Cancer Campus: Leading European comprehensive cancer center combining clinical oncology with translational research; a benchmark European peer for combined hospital-research oncology scale and theranostics capabilities.
• Institut Curie: French comprehensive cancer center combining a specialty hospital with a renowned research center, including radioisotope therapy programs; a structural analog for a public-mission oncology hospital-research hybrid.
• Karolinska Comprehensive Cancer Center: Swedish academic comprehensive cancer center embedded in Karolinska University Hospital, integrating oncology clinical care with translational research across radiotherapy, surgery, and systemic therapy.
• European Institute of Oncology (IEO Milan): Major European specialty oncology hospital with integrated research (IEO Monzino); comparable in offering surgical, radiotherapy, and systemic oncology with a strong clinical-trial pipeline.

Direct peers

• Centrum Onkologii im. prof. F. Łukaszczyka w Bydgoszczy: Another large Polish public comprehensive cancer center offering multidisciplinary oncology care and NFZ-funded services, directly competing for Polish oncology patients, research grants, and clinical talent.
• Narodowy Instytut Onkologii – Krakow Branch: Sister branch of the same State Research Institute in Krakow; provides overlapping oncology diagnostics, radiotherapy, and clinical research services under the same NFZ contracting and research infrastructure.
• Narodowy Instytut Onkologii – Warsaw (Parent HQ): The parent National Oncology Institute headquarters in Warsaw; operates the same comprehensive oncology and research mandate and shares institutional governance, clinical pathways, and grant funding with the Gliwice branch.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@narodowyinstytutonkologiiw1720
• Facebookfacebook.com/Onkologia.Gliwice
• LinkedInlinkedin.com/company/narodowy-instytut-onkologii-im.-marii-sk%C5%82odowskiej
• Instagraminstagram.com/gliwice_onkologia

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Narodowy Instytut Onkologii im. Marii Skłodowskiej